c19early.org COVID-19 treatment researchDexamethasoneDexamethasone (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Loading...
 
More
 

Supplementary Data — Dexamethasone for COVID-19: real-time meta analysis of 11 studies

@CovidAnalysis, June 2025, Version 8V8
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COPPER Kocks (DB RCT) -300% 4.00 [0.27-58.2] hosp. 2/4 0/2 Improvement, RR [CI] Treatment Control COPPER Kocks (DB RCT) -450% 5.50 [0.41-73.7] severe case 3/4 0/2 COPPER Kocks (DB RCT) -600% 7.00 [0.55-89.4] no recov. 4/4 0/2 Madamombe -130% 2.30 [1.60-3.40] death 245 (n) 427 (n) CoDEX Tomazini (RCT) 3% 0.97 [0.72-1.31] death 85/151 91/148 CoDEX Tomazini (RCT) 34% 0.66 [0.43-1.03] misc. 151 (n) 148 (n) RECOVERY Horby (RCT) 17% 0.83 [0.75-0.93] death 482/2,104 1,110/4,321 RECOVERY Horby (RCT) 21% 0.79 [0.64-0.97] ventilation 110/1,780 298/3,638 RECOVERY Horby (RCT) 9% 0.91 [0.85-0.97] no disch. 2,104 (n) 4,321 (n) Mourad 10% 0.90 [0.86-0.95] death Mourad 10% 0.90 [0.78-1.03] death 7,537 (n) 5,503 (n) Mourad 8% 0.92 [0.86-0.98] death Mourad 13% 0.87 [0.73-1.04] death 6,826 (n) 792 (n) Mourad 18% 0.82 [0.68-0.99] death 2,660 (n) 1,013 (n) EARLY-DEX Franco-Mor.. (RCT) -134% 2.34 [0.45-12.3] ventilation 4/58 2/68 EARLY-DEX Franco-Mor.. (RCT) -217% 3.17 [0.13-76.4] ICU 1/58 0/68 EARLY-DEX Franco-Mor.. (RCT) -17% 1.17 [0.52-2.62] ARDS 10/58 10/68 EARLY-DEX Franco-Mor.. (RCT) 3% 0.97 [0.67-1.39] hosp. time 58 (n) 68 (n) Yen -103% 2.03 [1.40-2.94] death 572 (n) 1,624 (n) Bhat (PSM) -35% 1.35 [0.88-2.07] death 46/529 34/529 Bhat (PSM) -46% 1.46 [1.06-2.00] no improv. 83/529 57/529 Zhao (PSM) 34% 0.66 [0.47-0.92] death 288 (n) 288 (n) Zhao (PSM) 33% 0.67 [0.46-0.99] death 288 (n) 288 (n) Garneau -31% 1.31 [0.09-19.0] death 1/13 1/17 Garneau -423% 5.23 [0.66-41.4] ICU 4/13 1/17 Garneau -155% 2.55 [0.95-6.83] hosp. time 13 (n) 17 (n) Bepouka -104% 2.04 [0.20-25.0] death 70 (n) 340 (n) Dexamethasone COVID-19 outcomes c19early.org June 2025 Favors dexamethasone Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit